These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24161254)

  • 1. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.
    Ganesh S; Iyer AK; Gattacceca F; Morrissey DV; Amiji MM
    J Control Release; 2013 Dec; 172(3):699-706. PubMed ID: 24161254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
    Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
    Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
    Ganesh S; Iyer AK; Morrissey DV; Amiji MM
    Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
    Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
    Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
    Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
    Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
    J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells.
    Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L
    Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
    Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD
    Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route.
    Jeannot V; Mazzaferro S; Lavaud J; Vanwonterghem L; Henry M; Arboléas M; Vollaire J; Josserand V; Coll JL; Lecommandoux S; Schatz C; Hurbin A
    Nanomedicine; 2016 May; 12(4):921-932. PubMed ID: 26724540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
    Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
    Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography.
    Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z
    Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy.
    Guo H; Wang H; Gao M; Deng H; Zhang Y; Gong J; Zhang W
    Carbohydr Polym; 2024 Nov; 344():122521. PubMed ID: 39218565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
    Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
    J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
    Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
    Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.